EMAS 临床指南：用于绝经后骨质疏松症的选择性雌激素受体调节剂。

EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.

机构信息

Palacios Institute of Woman's Health Antonio Acuna, Madrid, Spain.

出版信息

Maturitas. 2012 Feb;71(2):194-8. doi: 10.1016/j.maturitas.2011.11.010. Epub 2011 Dec 15.

DOI:10.1016/j.maturitas.2011.11.010

Abstract

Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.

摘要

骨质疏松症及其导致的骨折是全球人口老龄化带来的主要公共卫生问题。目前已有多种治疗方法，如双磷酸盐类药物、雷奈酸锶和最近的地舒单抗。本临床指南提供了选择性雌激素受体调节剂（SERMs）在绝经后妇女骨质疏松症管理中的临床应用证据。